<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="849">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 24, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04275388</url>
  </required_header>
  <id_info>
    <org_study_id>QF-XYP2001-1</org_study_id>
    <nct_id>NCT04275388</nct_id>
  </id_info>
  <brief_title>Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia</brief_title>
  <official_title>A Prospective, Randomized, Open, Parallel Controlled, Multicenter Clinical Study of Xiyanping Injection in Combination With Conventional Treatment for the Evaluation of the Effectiveness and Safety of Novel Coronavirus Infection Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangxi Qingfeng Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangxi Qingfeng Pharmaceutical Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the investigators conduct a randomized, open-label trial to evaluate and compare the safety
      and efficacy of Xiyanping injection in patients with 2019-nCoV pneumonia.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 14, 2020</start_date>
  <completion_date type="Anticipated">December 14, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 14, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Sham Comparator group receive lopinavir / ritonavir ,Alpha-interferon inhalation treatment； experimental group receive lopinavir / ritonavir, Alpha-interferon inhalation plus Xiyanping injection.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical recovery time</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>From the beginning of study drug use to fever, respiratory rate, blood oxygen saturation to normal and cough relief, and maintained for at least 72 hours or more, calculated in hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete fever time</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>From the beginning of research drug use to body temperature &lt;37.3 ℃ (underarm) or mouth temperature ≤37.5 ° C, or anal or ear temperature ≤37.8 ° C, and maintained for 24h or more</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cough relief time</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>Cough score &quot;day + night&quot; from the beginning of study medication to cough ≤ 1 point, and maintained for 24 hours and above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virus negative time</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>From the beginning of the study drug to two consecutive times (sampling interval of at least 1 day)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe or critical neocoronavirus pneumonia</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>Defined as the proportion of subjects exacerbated during treatment and meeting the diagnostic criteria for severe or critical neocoronavirus pneumonia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">348</enrollment>
  <condition>2019 Novel Coronavirus Pneumonia</condition>
  <arm_group>
    <arm_group_label>Xiyanping injection +other drugs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Xiyanping injection Xiyanping injection: 10-20ml daily, Qd, the maximum daily dose does not exceed 500mg (20mL) Other drugs: Lopinavir tablet or Ritonavir tablet+Alpha-interferon nebulization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>other drugs</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lopinavir tablet or Ritonavir tablet+Alpha-interferon nebulization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xiyanping injection</intervention_name>
    <description>Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet or Ritonavir tablet+Alpha-interferon nebulization, for 7-14 days,</description>
    <arm_group_label>Xiyanping injection +other drugs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir / ritonavir, alpha-interferon nebulization</intervention_name>
    <description>Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization</description>
    <arm_group_label>Xiyanping injection +other drugs</arm_group_label>
    <arm_group_label>other drugs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged between 18 and 70 years, extremes included, male or female

          2. Fever (armpit temperature ≥37.3 ° C, or mouth temperature ≥38.0 ° C, or anal or ear
             temperature ≥38.6 ° C) ≤7 days according to the official guideline &quot;Pneumonia
             Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 5)&quot;

          3. Laboratory test (RT-PCR) confirms infection 2019-nCoV

          4. No previous or experimental treatment for pneumonia associated with a novel
             coronavirus infection. Patients who have been treated with proprietary Chinese
             medicines or lopinavir / ritonavir tablets for less than 3 days can be enrolled

          5. Informed Consent Form (ICF) signed voluntarily

          6. Based on the investigator's judgment, the subject / legal guardian is considered
             reliable and able to comply with this program, visit plan and medication arrangement

        Exclusion Criteria:

          1. Suffer from diseases that need to be distinguished from new coronavirus infection
             pneumonia, such as tuberculosis, bacterial or viral pneumonia other than new
             coronavirus pneumonia, hospital-acquired pneumonia, and other pathogenic
             microorganisms pneumonia;

          2. Patients with basic diseases such as primary immunodeficiency disease, acquired
             immunodeficiency syndrome, congenital respiratory malformations, abnormal lung
             development, aspiration pneumonia, lung malignant tumors, etc .;

          3. Researchers have judged that previous or current diseases may affect patients'
             participation in the trial or influence the outcome of the study, including: malignant
             disease, autoimmune disease, liver and kidney disease, blood disease, neurological
             disease, and endocrine Disease; currently suffering from diseases that seriously
             affect the immune system, such as: human immunodeficiency virus (HIV) infection, or
             the blood system, or splenectomy, organ transplantation, etc .;

          4. Subjects with: asthma requiring daily treatment, any other chronic respiratory
             disease, respiratory bacterial infections such as purulent tonsillitis, acute
             tracheobronchitis, sinusitis, otitis media, and other respiratory tracts that affect
             clinical trial evaluation Disease: Chest CT confirmed patients with basic lung
             diseases such as severe interstitial lung disease and bronchiectasis;

          5. Patients diagnosed with severe, critically recurrent coronavirus infection, pneumonia,
             or need mechanical ventilation or need systemic antihormonal treatment;

          6. Breastfeeding or pregnancy test result is positive during the screening period or
             test;

          7. The research drug Xiyanping injection or a drug with similar efficacy (see Prohibition
             of Medication) has been used for more than 3 days during screening.

          8. Allergic constitution (persons who are allergic to more than 2 kinds of substances),
             people who are allergic to similar drugs in the past or those who are known to be
             allergic to the ingredients and auxiliary materials in the test drugs;

          9. Patients who have participated in other clinical trials in the past 3 months;

         10. The investigator determines that it is not appropriate to participate in a clinical
             trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hongzhou Lu, Master</last_name>
    <phone>021-37990333</phone>
    <email>lunliweiyuanhui2009@126.com</email>
  </overall_contact>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 17, 2020</study_first_submitted>
  <study_first_submitted_qc>February 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2020</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

